AstraZeneca (LON:AZN) Stock Price Down 9% – Time to Sell?

AstraZeneca PLC (LON:AZN)’s share price was down 9% on Monday . The stock traded as low as £114.14 and last traded at £115. Approximately 11,511,431 shares changed hands during mid-day trading, a decline of 61% from the average daily volume of 29,523,875 shares. The stock had previously closed at £126.32.

Analyst Ratings Changes

Several analysts have issued reports on AZN shares. Deutsche Bank Aktiengesellschaft restated a “sell” rating and set a £115 price objective on shares of AstraZeneca in a research note on Tuesday, July 28th. Berenberg Bank reiterated a “buy” rating and issued a £160 price target on shares of AstraZeneca in a report on Tuesday, July 28th. Jefferies Financial Group reissued a “buy” rating and set a £175 price target on shares of AstraZeneca in a research report on Monday. Finally, Citigroup raised their price objective on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and an average target price of £152.17.

AstraZeneca Price Performance

The company has a market capitalization of £178.35 billion, a price-to-earnings ratio of 17.32, a price-to-earnings-growth ratio of 0.86 and a beta of 0.23. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59. The business has a fifty day moving average price of £134.04 and a 200 day moving average price of £140.23.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.